A Guide to Pfizer/BioNTech’s COVID-19 Vaccine

The first COVID-19 vaccine that’s likely to go into any American arms is Pfizer’s mRNA vaccine, which was designed and developed by the German biotech company BioNTech. Here, we give a rundown of basic facts about the vaccine and an overview of how it works.

Quick Summary

Vaccine name: BNT162b2

Design type: mRNA

Dose number: 2, 21 days apart

Efficacy: 95% efficacy in preventing symptomatic COVID-19 in adults without prior evidence of infection a week or more after receipt of the second dose.

Safety: No serious safety concerns reported. The shots, however, routinely elicit a fairly strong temporary reaction in many people that can include injection site pain, fatigue, headache and chills.

Expected dose availability: Worldwide, up to 50 million doses, or enough for approximately 25 million people, by the end of 2020, with up to 1.3 billion doses expected in 2021.

Expected timeline: First doses not available in U.S. until at least a few days after Dec. 10, when an advisory committee is meeting to review the company’s emergency use authorization submission to the Food and Drug Administration.

Operation Warp Speed involvement: No support for the trials or research and development, but the U.S. government inked a $1.95 billion deal in July as part of OWS to buy 100 million doses, with the potential to acquire up to 500 million more, assuming the vaccine is authorized.

Storage considerations: -70°C (-94°F) for long-term storage; after thawing, vaccine vials can be stored at refrigerator temperatures for up to five days.

The Pfizer/BioNTech vaccine is widely expected to be the first COVID-19 vaccine authorized for use in the U.S. The companies released promising interim results from a phase 3 trial on Nov. 9, and on Nov. 18 announced a final efficacy of 95% in preventing disease among adults without prior evidence of a SARS-CoV-2 infection.

Two days later, the company submitted its application to the FDA to receive an emergency use authorization, or EUA, for its vaccine in people 16 years of age and older. The FDA is conducting a thorough review — including an analysis of the raw data — of the vaccine’s safety and efficacy, and will make a determination about an EUA sometime after Dec. 10, which is when an outside panel of experts advising the agency is meeting to review the data.

In a sign the FDA is likely to grant the EUA, the agency wrote in meeting materials released before the advisory committee’s meeting that the vaccine was “highly effective” in preventing confirmed COVID-19 and that the safety profile was “favorable,” with “no specific safety concerns identified that would preclude issuance of an EUA.”

The U.K. authorized the vaccine for emergency use on Dec. 2 and began immunizing people on Dec. 8. Canada authorized the vaccine on Dec. 9.

Pfizer/BioNTech Q&A
  • What is in the vaccine and how does it work?

As with most other COVID-19 vaccine designs, the Pfizer/BioNTech mRNA vaccine works by triggering an immune response against the spike protein of the SARS-CoV-2 virus, which sits on the surface of the virus and is what the virus uses to enter cells.

The vaccine is made of modified messenger RNA, or mRNA, wrapped in a special blend of fatty molecules known as lipid nanoparticles. The mRNA provides instructions for cells to make their own spike proteins, prompting the body to generate protective antibodies and activate T cells. The lipids help deliver the RNA into cells and prevent it from being degraded too quickly.

As the Centers for Disease Control and Prevention has explained, there is no way to catch COVID-19 from this type of vaccine because the vaccine is not made of a virus. And because the mRNA from the vaccine doesn’t enter the nucleus — the part of the cell that houses DNA — it “does not affect or interact with a person’s DNA,” contrary to some online rumors.

  • How was the vaccine developed?

German company BioNTech designed multiple mRNA vaccine candidates after the genetic sequence of the SARS-CoV-2 virus became public in January and partnered with Pfizer in March.

Early phase clinical trials showed that two leading mRNA designs triggered neutralizing antibody responses that were better than those from people recovering from natural COVID-19 infection, with no serious adverse events. 

But one candidate — BNT162b2, which prompts cells to make a full-length spike protein — did so with fewer side effects than the other. Based on the trial results and preclinical tests, the companies decided to move forward to a combined phase 2/3 randomized controlled trial testing two 30 microgram doses of BNT162b2 on volunteers.

The phase 2/3 trial began in late July, ultimately enrolling around 44,000 people in the U.S., Argentina, Brazil, Germany, South Africa and Turkey. Enrollment was expanded past the 30,000 initial target in September to include people infected with HIV, hepatitis B and hepatitis C, and to add teens as young as 16 years old. In October, the age requirement was lowered to 12 years old. Because of the limited data available on this population, however, Pfizer did not ask to include the 12- to 15-year-old age group in its EUA request.

  • How effective is the vaccine?

Pfizer announced in a Nov. 18 press release that its vaccine was 95% effective in preventing COVID-19 disease in adults without prior evidence of infection, as measured seven or more days after the second dose. The company reported similar efficacy rates across a variety of demographics, including racial and ethnic minorities and older adults.

The trial only looked at whether the vaccine prevented symptomatic disease, not whether the vaccine prevented people from becoming infected or whether the vaccine kept people from transmitting the virus. Additional data from the ongoing trial and other studies may help to answer these questions, as well as how long a vaccinated person is protected, which is unknown.

Data summarized by the FDA ahead of the advisory committee’s Dec. 10 meeting additionally suggested that disease protection may occur after a single dose, with an estimated efficacy of 82%. But because the trial did not test a single shot, the agency could not reach a conclusion about how well a single dose actually works.

A 95% efficacy does not mean that 95% of people will be protected by the vaccine. Instead, the math is a bit more complicated — and is a relative risk reduction calculation based on 162 cases of COVID-19 occurring in the placebo group and eight in the vaccine group. 

As University of Florida biostatistician Natalie Dean explained in a Twitter thread, a 95% efficacy roughly means a vaccinated person has a 95% reduced risk of becoming sick, compared with a similar person who wasn’t immunized.

Dean also noted that it’s important to differentiate between efficacy, which is the metric used in a clinical trial, and real-world performance as measured in observational studies, which is called effectiveness. It’s possible that outside of the idealized conditions of a randomized controlled trial, the vaccine won’t perform quite as well, although 95% efficacy is still very good.

The preferred shingles vaccine, Shingrex, for example, has an efficacy of 91.2% in preventing postherpetic neuralgia in people older than 50.

In terms of the ability of the vaccine to reduce the risk of developing more serious COVID-19 illness, nine cases of severe COVID-19 occurred in the placebo group versus one in the vaccinated group.

The FDA briefing document explained that the small number of severe COVID-19 cases “limits the overall conclusions that can be drawn; however, the case split does suggest protection from severe COVID-19 disease.”

  • How safe is the vaccine?

No serious safety concerns have been reported. Anyone getting the vaccine, however, should be prepared for unpleasant side effects, including pain, redness and swelling at the site of injection, as well as fatigue, headache, chills and fever.

According to the data released ahead of the FDA advisory committee, these types of reactions were relatively common and tended to be more frequent and severe in younger people.

Underscoring the degree to which these should not be underestimated by the public, a nurse who participated in Pfizer’s trial and suspects she was in the vaccinated group shared in JAMA Internal Medicine that she had a high fever and felt quite ill for nearly two days after receiving her second shot.

As she noted, these effects were transient and “a normal sign of reactogenicity signaling an effective immune response” — in other words, the vaccine doing precisely what it should be doing. But it still caught her off guard because she wasn’t warned about it — and she counseled physicians and others to communicate that these responses are expected, so vaccine recipients are prepared.

Serious adverse events, which refer to potentially life-threatening or disabling events, occurred in fewer than 1% of participants, and at similar rates in those vaccinated and those not. The few instances the FDA considered possibly related to the vaccine in its briefing summary included one case of a shoulder injury and one instance of lymphadenopathy, or swelling of the lymph nodes, following vaccination (nonserious cases of lymphadenopathy affected 0.3% of those vaccinated, above the rate of the unvaccinated).

Among nonserious adverse events, the FDA noted that there were four cases of Bell’s palsy, a form of temporary facial paralysis, in the vaccine group, and none in the placebo group. This may not mean anything, as the frequency in the vaccine group was not higher than would be expected in the general population, but the agency plans to recommend monitoring for the condition as the vaccine is rolled out into a larger population.

After Britain began its rollout of the vaccine, two National Health Service staff members experienced allergic reactions following vaccination, prompting the government to advise “on a precautionary basis” that people with a history of “significant” allergic reactions should not get the vaccine. Both NHS workers carried adrenaline shots, best known as EpiPens, and are recovering well.

Because many vaccines have the potential to cause allergic reactions, albeit very rarely, it’s common for people with a history of such reactions to consult with their physicians before taking any vaccine. The U.K.’s Medicines and Healthcare Products Regulatory Agency will be investigating the cases.

  • Why does the vaccine need to be kept so cold?

The extreme cold is necessary to keep the highly sensitive lipid-encapsulated RNA molecules from degrading. Logistically, this cold chain requirement poses an extra hurdle in distributing the vaccine, since many potential vaccination sites lack the appropriate ultracold freezers and may not have a ready source of dry ice.

Pfizer has tried to mitigate some of these challenges by creating specialized “thermal shippers” for its vaccine that will maintain ultracold temperatures for up to 10 days if unopened and can store vials for as long as a month if refilled every five days with dry ice.

Rival company Moderna, which also used an mRNA design for its COVID-19 vaccine candidate, also requires freezing temperatures, but they are less severe, due to differences in the particular lipid nanoparticles used. The company announced in November that its vaccine should remain stable long-term at standard freezer temperatures and should last for 30 days in a refrigerator.

Leave a Reply

Your email address will not be published. Required fields are marked *